Dr. M. Jalving is a medical oncologist at the University Medical Centre Groningen, Groningen, the Netherlands. She completed her basic medical and specialist training in Groningen, with training periods at the Royal Marsden Hospital, Sutton, UK and at the Oxford Radcliffe Hospitals Trust, Oxford, UK. She obtained an MSc in Experimental Therapeutics at Oxford University and her PhD on apoptosis in colorectal cancer at the University of Groningen.

She is involved in patient care, teaching and research. Her main interests are melanoma and gynaecological cancer and is she active in early phase clinical research. Her research focuses on understanding the altered metabolism of cancer in patients and utilising the altered metabolic profile as a potential treatment target.  Apart from laboratory studies, she performs and coordinates clinical trials. In early phase trials she has a particular interest in drugs targeting DNA repair and in novel immunotherapeutic strategies. She has received various grants, including grants from the Dutch Cancer Society and Cancer Research UK.

Dr. Jalving is a member of the Dutch Cancer society (NVMO), the Dutch Internal Medicine Society (NIV), the European Society for Medical Oncology (ESMO), the American Association for Cancer Research (AACR). She is currently in the ESMO Melanoma Faculty and member of the ESMO Climate Change Task Force.